Citi Adds WuXi Bio to 90-Day Positive Catalyst Watch, Expects Potential Full-Year Guidance Raise in Q4
Stock News
Nov 05
Citi has added WuXi Biologics (02269.HK) to its 90-day positive catalyst watch list, according to a research report.
The bank believes the company may raise its overall guidance in the fourth quarter, and the biosimilar development agreement reached with Fresenius could also prompt the company to lift its long-term revenue target for contract manufacturing organization (CMO) business.
Citi also noted that WuXi Biologics is one of its preferred AI-driven drug discovery (AIDD) beneficiary stocks, and believes the company's AIDD capabilities are currently undervalued by the market.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.